Identity and synonyms
Do not merge with Mod GRF(1–29).
Synonyms: CJC-1295 · DAC-GRF
Peptide or peptide-related · Peptide or peptide derivative
Detailed molecular class: GHRH analogue
Supplied sequence or chemical reference
See identity note; no supplier sequence accepted as verification.
Commercial identity or variant awaiting clarification.
Mechanism
Long-acting albumin-binding GHRH analogue increases GH/IGF-1; GH pulsatility can persist.
Evidence and critical reading
Reported scientific and empirical uses
GH/IGF hormonal axis
Handbooks describe GH/IGF-1 elevation, body composition and recovery. These objectives have different support: raising a biomarker does not demonstrate strength gain, better sleep or longer life.
Human evidence
Two short randomized studies assessed pharmacology in healthy adults, not injury healing, longevity or a CJC/ipamorelin stack.
Preclinical evidence
Mechanistic GH-axis effects are not clinical outcome validation.
Critical reading and limitations
Short randomized pharmacology trials showed sustained GH/IGF-1 elevation in healthy adults. They do not establish sports outcomes, years of safety or efficacy of CJC+ipamorelin. These results must not be reused as evidence for the no-DAC compound.
Evidence applies to the exact molecule, formulation, route, population and endpoint studied. Supplier identity, purity and clinical equivalence are unverified.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Human-study exposure
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Empirical handbook
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Reported by Peptide Handbook — James B. LaValle, Gordon Crozier, Joseph P. Cleaver and Andrew Heyman
600 mcg · Amount per administration
- Frequency
- Once weekly
- Duration
- Not stated on selected page.
- Route
- Route not restated in that subsection; not inferred here.
- Context
- CJC explicitly identified as DAC.
- Presentation
- Not stated on selected page.
- Interpretation
- Does not validate efficacy or safety of this regimen; attributed to the handbook.
manual01 · Page 36 · October 16, 2026
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Regulation and safety
Jurisdiction-specific regulatory context
Jurisdiction-specific approval not verified in this card; do not infer global nonapproval.
Adverse effects and unknowns
Limited clinical data; FDA reports tachycardia and systemic vasodilatory reactions. Attribution and incidence require full study assessment.
Contraindications
See supported safety statements and exact product label; a complete contraindication set has not been established for this catalog material.
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Only explicitly cited interactions may be asserted; unstudied combinations remain unknown, not interaction-free.
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
PMID16352683 · Randomized pharmacology trials
Healthy adults, ages 21–61.
Subcutaneous long-acting CJC.
Sustained GH and IGF-1 elevation.
Biomarkers; does not prove performance, longevity or the no-DAC compound.
PMID17018654 · Human pharmacology
Healthy men, ages 20–40.
Single administration; subsequent GH measurements.
Basal/mean GH increased with preserved pulsatility.
Does not support universal abolition of pulses by DAC; not a sports-benefit trial.
Trials attributed in the package
NCT00267527 · A Study to Evaluate CJC 1295 in HIV Patients With Visceral ObesityRegistry status: TerminatedLast update posted: October 16, 2006Query verification: October 16, 2026
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
CJC-1295 · 1 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry queryNCT00267527 · A Study to Evaluate CJC 1295 in HIV Patients With Visceral ObesityRegistry status: TerminatedLast update posted: October 16, 2006Query verification: October 16, 2026
Source issues and references
The loss-of-pulsatility explanation must be contrasted with the human study observing preserved pulsatility. · manual07 · PMID17018654 · Page 15
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PMID16352683
Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA.
October 16, 2026
- PMID17018654
Ionescu M, Frohman LA.
October 16, 2026
- R06
- R10
- R11
- manual01
Peptide Handbook — James B. LaValle, Gordon Crozier, Joseph P. Cleaver and Andrew Heyman
James B. LaValle; Gordon Crozier; Joseph P. Cleaver; Andrew Heyman
October 16, 2026
Bibliographic attribution only. The supplied handbook is a secondary empirical practice source, not clinical verification. Private source files and supplier/download destinations are not provided here.
- manual07
2.pdf
October 16, 2026
- pdf01
PEPNEXA 2.pdf
October 16, 2026
- pdf02
ELLA PEPTIDES.pdf
October 16, 2026
- pdf03
zlz list 26.8.5.pdf
October 16, 2026
- pdf05
PEPNEXA.pdf
October 16, 2026
- pdf07
US Peptide MangerCorp(1).pdf
October 16, 2026
- pdf09
PeptideFactory.pdf
October 16, 2026